-
5-({4-[2-(4-oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione
-
ChemBase ID:
153242
-
Molecular Formular:
C20H18N2O5S
-
Molecular Mass:
398.43232
-
Monoisotopic Mass:
398.09364269
-
SMILES and InChIs
SMILES:
c1ccc2c(c1)C(=O)N(CO2)CCOc1ccc(cc1)CC1C(=O)NC(=O)S1
Canonical SMILES:
O=C1NC(=O)C(S1)Cc1ccc(cc1)OCCN1COc2c(C1=O)cccc2
InChI:
InChI=1S/C20H18N2O5S/c23-18-17(28-20(25)21-18)11-13-5-7-14(8-6-13)26-10-9-22-12-27-16-4-2-1-3-15(16)19(22)24/h1-8,17H,9-12H2,(H,21,23,25)
InChIKey:
RFMNEXVCPAPDRA-UHFFFAOYSA-N
-
Cite this record
CBID:153242 http://www.chembase.cn/molecule-153242.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
|
IUPAC name
|
|
5-({4-[2-(4-oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione
|
|
|
|
|
IUPAC Traditional name
|
|
5-({4-[2-(4-oxo-2H-1,3-benzoxazin-3-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione
|
|
|
|
|
Synonyms
|
|
5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione
|
|
DRF 2519
|
|
|
|
|
MDL Number
|
|
|
PubChem SID
|
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
|
Acid pKa
|
7.6135864
|
H Acceptors
|
5
|
H Donor
|
1
|
LogD (pH = 5.5)
|
2.6669805
|
LogD (pH = 7.4)
|
2.4660544
|
Log P
|
2.670273
|
Molar Refractivity
|
103.3802 cm3
|
Polarizability
|
39.98293 Å3
|
Polar Surface Area
|
84.94 Å2
|
Rotatable Bonds
|
6
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
D6567
|
Biochem/physiol Actions DRF-2519 is a dual PPARα/γ activator. DRF-2519 has better reduction of plasma insulin, triglyceride, and free fatty acid levels than those treated with rosiglitazone. |
PATENTS
PATENTS
PubChem Patent
Google Patent